<!DOCTYPE html>
<html>
  <head>
    <title>Lipid lowering</title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta charset="utf-8">
    <!-- Bootstrap -->
    <link href="//netdna.bootstrapcdn.com/bootswatch/3.2.0/flatly/bootstrap.min.css" rel="stylesheet" media="screen">
    <link href="/css/site.css" rel="stylesheet" media="screen">
    <link href="/css/syntax.css" rel="stylesheet" media="screen">

    <!-- HTML5 Shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!-- WARNING: Respond.js doesn't work if you view the page via file:// -->
    <!--[if lt IE 9]>
      <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
      <script src="https://oss.maxcdn.com/libs/respond.js/1.3.0/respond.min.js"></script>
    <![endif]-->
<script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-48968311-4', 'jandecaluwe.com');
  ga('send', 'pageview');

</script>
  </head>

  <body>

    <!-- Fixed navbar -->
    <div class="navbar navbar-default navbar-fixed-top">
      <div class="container">
        <div class="navbar-header">
          <button type="button" class="navbar-toggle" data-toggle="collapse" data-target=".navbar-collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </button>
          <a class="navbar-brand" href="/">Rory’s notes</a>
        </div>
        <div class="navbar-collapse collapse">

          <ul class="nav navbar-nav navbar-left">
 
          </ul>

          <ul class="nav navbar-nav navbar-right">
            <li class="active"><a href="/notes/">notes</a></li>
          </ul>

        </div><!--/.nav-collapse -->
      </div>
    </div>


<div class="container">

  <ol class="breadcrumb">
    <li><a href="/">Home</a></li>
      <li><a href="/notes/">notes</a></li>
      <li><a href="/notes/cardiovascular/">cardiovascular</a></li>
      <li><a href="/notes/cardiovascular/cardiovasulcar risk management/">cardiovasulcar risk management</a></li>
      <li class="active">Lipid lowering</li>
  </ol>

  <div class="page-header">
 
    <h1>Lipid lowering</h1>
  </div>

  <div class="row">

    <div class="col-md-3" role="navigation"> 
 
      <div class="sidebar" data-spy="affix" data-offset-top="80" data-offset-bottom="60">
        <div class="well">
          <a href="#"><strong>Lipid lowering</strong></a>
          <div class="toc">
<ul>
<li><a href="#secondary-causes-of-lipid-abnormalities">Secondary causes of lipid abnormalities</a></li>
<li><a href="#lipid-lowering-for-people-with-combined-cvd-risk-between-10-20">Lipid lowering for people with combined CVD risk between 10-20%</a></li>
<li><a href="#lipid-lowering-for-people-with-combined-cvd-risk-6220">Lipid lowering for people with combined CVD risk >20%</a></li>
<li><a href="#speicific-lipid-profiles">Speicific lipid profiles:</a></li>
<li><a href="#statin">Statin:</a><ul>
<li><a href="#monitoring">Monitoring</a></li>
<li><a href="#adverse-effects">Adverse effects:</a><ul>
<li><a href="#hepatotoxicity">Hepatotoxicity</a></li>
</ul>
</li>
<li><a href="#acute-kidney-injury">Acute kidney injury</a></li>
<li><a href="#type-2-dm">Type 2 DM</a></li>
<li><a href="#memory">Memory</a></li>
<li><a href="#myalgia">Myalgia</a><ul>
<li><a href="#management-of-statin-myalgia">management of statin myalgia</a></li>
</ul>
</li>
<li><a href="#interacting-medication-and-max-simvastatin-dose">Interacting medication and max. simvastatin dose</a></li>
<li><a href="#statin-safety-monitoring">Statin safety monitoring</a></li>
</ul>
</li>
<li><a href="#nicotinic-acid">Nicotinic acid</a></li>
<li><a href="#ezetimibe">Ezetimibe</a></li>
<li><a href="#fibrates">Fibrates</a></li>
</ul>
</div>

        </div>
      </div>
    </div>
 
    <div class="content">
      <div class="col-md-6" role="main">
        <blockquote>
<p>markedly elevated TAGS preclude estimation of HDL = unreliable</p>
</blockquote>
<ul>
<li>
<p>TC >8 or a TC:HDL-C ratio >8 </p>
<ul>
<li>Lipid lowerging treatment usually recommended regardless of combined CVD risk</li>
</ul>
</li>
</ul>
<h3 id="secondary-causes-of-lipid-abnormalities">Secondary causes of lipid abnormalities</h3>
<ul>
<li>
<p>diet</p>
</li>
<li>
<p>etoh</p>
</li>
<li>
<p>hypothyroidism</p>
</li>
<li>
<p>DM</p>
</li>
<li>
<p>liver disease</p>
</li>
<li>
<p>nephrotic syndrome</p>
</li>
<li>
<p>steroid treatment</p>
</li>
<li>
<p>pregnancy</p>
</li>
<li>
<p>consider genetic lipid disorder if:</p>
<ul>
<li>
<p>TC ≥ 8mmol/L </p>
</li>
<li>
<p>premature fhx of coronary artery disease</p>
</li>
</ul>
</li>
</ul>
<h3 id="lipid-lowering-for-people-with-combined-cvd-risk-between-10-20">Lipid lowering for people with combined CVD risk between 10-20%</h3>
<ul>
<li>
<p>Discuss benefits (and risks) of statins</p>
</li>
<li>
<p>Lifestyle</p>
</li>
<li>
<p>Repeat lipid profile 6-12 months</p>
</li>
<li>
<p>Aim: achieve moderate reduction in LDL-C</p>
<ul>
<li>
<p>no target for those with combined risk \&lt;20%</p>
</li>
<li>
<p>remeasure @ next CVRA</p>
</li>
</ul>
</li>
<li>
<p>Consider treatable primary cause for a dyslipidaemia</p>
<ul>
<li>
<p>High saturated fat diet</p>
</li>
<li>
<p>excessive EtOH</p>
</li>
<li>
<p>hypothyroidism</p>
</li>
<li>
<p>diabetes</p>
</li>
<li>
<p>liver disease</p>
</li>
<li>
<p>nephrotic syndrome</p>
</li>
<li>
<p>steroid treatment</p>
</li>
</ul>
</li>
<li>
<p>consider lower dose statin</p>
<ul>
<li><strong>simvastatin 40mg or atorvastatin 20mg</strong></li>
</ul>
</li>
</ul>
<h3 id="lipid-lowering-for-people-with-combined-cvd-risk-6220">Lipid lowering for people with combined CVD risk >20%</h3>
<ul>
<li>
<p>statin treatment strongly recommended</p>
<ul>
<li><strong>Atorvastatin: 20-40mg</strong></li>
</ul>
</li>
<li>
<p>no evidence that outcomes are improved by adding other cholesterol-lowering drugs to a statin</p>
</li>
</ul>
<h3 id="speicific-lipid-profiles">Speicific lipid profiles:</h3>
<ul>
<li>
<p>predominant hypercholesterolaemia</p>
<ul>
<li>
<p>statins = first line</p>
</li>
<li>
<p>can be used in combination with ezetimibe, nicotinic acid or resins</p>
<ul>
<li>
<p>lower TC and LDL-C</p>
</li>
<li>
<p>Nicotinic acid / fibrates may be considered if low HDL \&lt;1</p>
</li>
<li>
<p>very low HDL \&lt;0.7 may require specialist review</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>predominant hypertriglyceridaemia</p>
<ul>
<li>
<p>identify lifestyle</p>
</li>
<li>
<p>or any primary cause</p>
</li>
<li>
<p>correctin these factors may make drug treatment unecessary</p>
</li>
<li>
<p>Nicotinic acid, acipimox or fibrates most appropriate</p>
</li>
<li>
<p>statins usually not effective if TAG >5</p>
</li>
</ul>
</li>
<li>
<p>combined</p>
<ul>
<li>
<p>lifestyle</p>
</li>
<li>
<p>statin and nicotinic or gibrate</p>
</li>
</ul>
</li>
</ul>
<h3 id="statin">Statin:</h3>
<ul>
<li>
<p>Simvastatin</p>
</li>
<li>
<p>Atorvastatin</p>
</li>
<li>
<p>Pravastatin</p>
</li>
<li>
<p>Rosuvstatin (NS)</p>
</li>
<li>
<p>CYP 3A4</p>
</li>
<li>
<p>in those taking statin for 5yrs</p>
<ul>
<li>
<p>NNT to prevent one non fatal MI = 39</p>
</li>
<li>
<p>NNT to prevent one death = 83</p>
</li>
</ul>
</li>
</ul>
<h4 id="monitoring">Monitoring</h4>
<ul>
<li>
<p>non fasting lipids q3-6/12 until person stable then once/year</p>
<ul>
<li>
<p>moderate reduction in LDL-C</p>
<ul>
<li>
<p>no specific target 20%</p>
</li>
<li>
<p>higher reduction if risk >20%</p>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<h4 id="adverse-effects">Adverse effects:</h4>
<ul>
<li>
<p>Muscle symptoms</p>
</li>
<li>
<p>medicine interactions</p>
</li>
<li>
<p>Major organ effects</p>
<ul>
<li>hepatic/renal</li>
</ul>
</li>
<li>
<p>metabolism</p>
<ul>
<li>risk of T2DM</li>
</ul>
</li>
<li>
<p>Memory</p>
</li>
</ul>
<h5 id="hepatotoxicity">Hepatotoxicity</h5>
<ul>
<li>
<p>highly unsuual</p>
<ul>
<li>“negligible”</li>
</ul>
</li>
<li>
<p>routine monitoring unnecessary</p>
</li>
<li>
<p>UK/USA guidelines recommend baseline</p>
<ul>
<li>ALT unlikley provide useful information unless suspect liver dysfunction</li>
</ul>
</li>
<li>
<p>elevated ALT/AST less than 3%</p>
<ul>
<li>
<p>not significantly differnet from those taking placebo</p>
</li>
<li>
<p>often return to normal wihtout pt. needing to stop taking statin</p>
</li>
</ul>
</li>
<li>
<p>if ALT markedly elevated</p>
<ul>
<li>
<p>risk v benefit should be revisitied</p>
</li>
<li>
<p>used in caution if 3x upper limit of N</p>
</li>
<li>
<p>lower dose may be appropriate if choose to start</p>
</li>
<li>
<p>NAFLD = mild-moderate rise</p>
<ul>
<li>
<p>Atrovastatin = reduce aminotransferase levels in thi sgroup</p>
</li>
<li>
<p>mildly abnormal levels in NAFLD = <strong>not</strong> contraindication for statin therapy</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>reasonable to monitor if suspected liver dysfunction and elevated baseline or symptoms</p>
<ul>
<li>
<p>unexplained fatigue</p>
</li>
<li>
<p>weakness</p>
</li>
<li>
<p>loss of appetite</p>
</li>
<li>
<p>abdominal pain</p>
</li>
<li>
<p>dark-coloured urine</p>
</li>
<li>
<p>yellowing of skin or sclera</p>
</li>
</ul>
</li>
<li>
<p><em>request ALT only rather than LFTs</em></p>
</li>
</ul>
<h4 id="acute-kidney-injury">Acute kidney injury</h4>
<ul>
<li>
<p>risk slightly increased</p>
<ul>
<li>
<p>(muscle protein entering blood stream)</p>
</li>
<li>
<p>aged >40 and first 120days of ≥ 40mg simvastatin for hospitilisation for AKI</p>
<ul>
<li>
<p>relative risk increase by 1/3</p>
</li>
<li>
<p>NNH = 1700</p>
</li>
<li>
<p>those with CKD and statin not at increased risk</p>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<h4 id="type-2-dm">Type 2 DM</h4>
<ul>
<li>
<p>increase risk of developing diabetes</p>
<ul>
<li>
<p>increases according to teratment intensity</p>
<ul>
<li>
<p>20-40mg simvastatin (moderate)</p>
<ul>
<li>NNH = 1000</li>
</ul>
</li>
<li>
<p>high ≥ 40mg</p>
<ul>
<li>NNH = 250</li>
</ul>
</li>
</ul>
</li>
<li>
<p>risk outweighed by reduced risk of cardiovascualr events</p>
<ul>
<li>
<p><strong>except</strong></p>
<ul>
<li>
<p>\&lt;40yo</p>
</li>
<li>
<p>>75yo </p>
</li>
<li>
<p>low LDL - C</p>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>in adults with DM</p>
<ul>
<li>
<p>statin treatment decrease relative risk by 2-%</p>
</li>
<li>
<p>those most at risk of DM</p>
<ul>
<li>most to gain</li>
</ul>
</li>
</ul>
</li>
<li>
<p>if develop T2DM then conitnue statin</p>
</li>
</ul>
<h4 id="memory">Memory</h4>
<ul>
<li>
<p>no clear evidence that adverse effect</p>
<ul>
<li>
<p>observational data = link between memory loss and confusion</p>
</li>
<li>
<p>heart protection study and PROSPER:</p>
<ul>
<li>no significant difference in rate of cognitive decline</li>
</ul>
</li>
</ul>
</li>
<li>
<p>strategies if patient concerned re statin:</p>
<ul>
<li>
<p>swtiching stating,</p>
</li>
<li>
<p>taking low dose</p>
</li>
<li>
<p>trialing alterante day dosing</p>
</li>
</ul>
</li>
<li>
<p>reassured that any cognitive symptoms due to statin use:</p>
<ul>
<li>likely to resolve within 3-4 weeks of stopping treatment</li>
</ul>
</li>
</ul>
<h4 id="myalgia">Myalgia</h4>
<ul>
<li>
<p>with or without muscle weakness = most common adverse effect associated with statin use</p>
<ul>
<li>
<p>10% of people prescribed statins</p>
</li>
<li>
<p>not necesarily cause in all these people</p>
</li>
</ul>
</li>
<li>
<p>may be described as:</p>
<ul>
<li>
<p>muscle ache</p>
</li>
<li>
<p>heaviness</p>
</li>
<li>
<p>stiffness</p>
</li>
<li>
<p>cramping</p>
</li>
<li>
<p>tendon pain</p>
</li>
<li>
<p>nocturnal leg cramps may also occur</p>
</li>
</ul>
</li>
<li>
<p>weakness may occur wihtout discomfort</p>
<ul>
<li>
<p>inability to open jars</p>
</li>
<li>
<p>difficulty snapping their fingers / difficulty getting out of chair</p>
</li>
</ul>
</li>
<li>
<p>Statin - associated myalgia characterised by:</p>
<ul>
<li>
<p>symmetrical involvmenet of large and proximal muscel groups</p>
<ul>
<li>especially legs</li>
</ul>
</li>
<li>
<p>typically within 6mo of initiating statin</p>
</li>
</ul>
</li>
<li>
<p>when associated with muscle inflammation = <strong>myositis</strong></p>
<ul>
<li>
<p>usually with increase CK</p>
</li>
<li>
<p><strong>Rhabdomyolysis</strong></p>
<ul>
<li>
<p>inflammation -> muscle fibre breakdown -> myoglobin into bloodstream</p>
</li>
<li>
<p>criteria</p>
<ul>
<li>
<p>CK > 10x ULN</p>
</li>
<li>
<p>evidence of myoglobinaemia</p>
</li>
</ul>
</li>
<li>
<p>death due to Rhabdo in patients taking statin = extremely rare</p>
</li>
<li>
<p>NNH 8000 (taking statin for ≥ 40 years for 1 extra death)</p>
</li>
<li>
<p>immediately withdraw statin if:</p>
<ul>
<li>
<p>unexplained brownish-red coloured urine</p>
<ul>
<li>myoglobinuria (“tea brown”)</li>
</ul>
</li>
<li>
<p>decrease urine output</p>
</li>
<li>
<p>fatigue</p>
</li>
<li>
<p>muscle weakness</p>
</li>
</ul>
</li>
<li>
<p>tests;</p>
<ul>
<li>
<p>CK</p>
</li>
<li>
<p>Cr</p>
</li>
<li>
<p>electrolytes (Ca/PO4)</p>
</li>
<li>
<p>urine dipstick - haem</p>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>increase CK not necessarily diagnostic of pathology</p>
<ul>
<li>
<p>transient increase healthy people</p>
<ul>
<li>vigorous exercise</li>
</ul>
</li>
</ul>
</li>
<li>
<p>serious muscle cell damage</p>
<ul>
<li>
<p>co-morbid</p>
</li>
<li>
<p>dehydration</p>
</li>
<li>
<p>pre-existing renal impairment</p>
</li>
<li>
<p>insufficient evidecne to recommend coadministration of CoQ10 for prevention of statin-associated myalgia</p>
<ul>
<li>
<p>precursor of cholesterol</p>
</li>
<li>
<p>reductions thought to interfere with cellular respiration and result in muscle toxicity</p>
</li>
<li>
<p>muscle CoQ10 levels don’t correlate well with histological changes</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p><strong>risk factors</strong></p>
<ul>
<li>
<p>patient characteristics:</p>
<ul>
<li>
<p>Age >80</p>
</li>
<li>
<p>F</p>
</li>
<li>
<p>Ethnicity</p>
<ul>
<li>
<p>African/caribbean</p>
</li>
<li>
<p>asian - rosuvastatin</p>
</li>
</ul>
</li>
<li>
<p>small body size and frailty</p>
</li>
<li>
<p>excessive physical activity</p>
</li>
<li>
<p>Drinking >1L of grapefruit juice / day</p>
</li>
<li>
<p>personal / fhx or muscle symptoms</p>
</li>
<li>
<p>history of elevated CK</p>
</li>
<li>
<p>unexplained muscle cramps</p>
</li>
</ul>
</li>
<li>
<p>comorbidities</p>
<ul>
<li>
<p>hypothyroidism</p>
</li>
<li>
<p>CKD</p>
</li>
<li>
<p>DM - Type 1/2</p>
</li>
<li>
<p>Alcoholism</p>
</li>
<li>
<p>history of major surgery / recent procedure </p>
</li>
<li>
<p>infections</p>
</li>
</ul>
</li>
<li>
<p>medicines:</p>
<ul>
<li>
<p>high dose statins (simvastatin ≥ 80mg /day</p>
<ul>
<li>no longer recommended</li>
</ul>
</li>
<li>
<p>medicines that interact with statins</p>
</li>
<li>
<p>concurrent use of oral corticosteroids</p>
<ul>
<li>
<p>increase risk of developing muscles ysmtpoms</p>
<ul>
<li>
<p>3xF</p>
</li>
<li>
<p>2xM</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>substance use (missuse)</p>
</li>
</ul>
</li>
<li>
<p>Genetics</p>
<ul>
<li>
<p>inherited muscle disease</p>
</li>
<li>
<p>polymorphisms in CYP</p>
</li>
<li>
<p>drug transporter genes</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>stop simvastatin (and to a lesser degree atorvastatin)</p>
<ul>
<li>
<p><strong>erythromycin and clarithromycin</strong></p>
<ul>
<li>case reports with azithromycin/roxithromycin + atorvastatin but no clincially significant interactions are known to occur between these antibiotics and atorvastatin</li>
</ul>
</li>
<li>
<p><strong>azole antifungals</strong></p>
</li>
<li>
<p>Protease inhibitors</p>
<ul>
<li>anitvirals</li>
</ul>
</li>
<li>
<p>Gembibrozil</p>
</li>
<li>
<p>ciclosporin</p>
</li>
<li>
<p>Danazol</p>
</li>
</ul>
</li>
<li>
<p>Pravastatin mainly cleared by kidneys and fully subsidised alternative for those taking CYP active drugs</p>
<ul>
<li>pravastatin + fibrates = increase risk of muscle damage</li>
</ul>
</li>
<li>
<p>Rosuvastatin largely metabolised by antoher enxzye systems</p>
<ul>
<li>different interactions</li>
</ul>
</li>
<li>
<p>Genetic test</p>
<ul>
<li>
<p>SLCO1b1 on chromosone 12</p>
<ul>
<li>presence/absence single nucleotide polymorphism</li>
</ul>
</li>
<li>
<p>prevallence of 15%</p>
</li>
<li>
<p>1 copy:</p>
<ul>
<li>4.5x increase risk of myalgia</li>
</ul>
</li>
<li>
<p>2 copies</p>
<ul>
<li>17 x increase risk</li>
</ul>
</li>
<li>
<p>unsubsidised = 120$</p>
</li>
</ul>
</li>
<li>
<p>before initiating</p>
<ul>
<li>
<p>ask about history of muscle symptoms</p>
</li>
<li>
<p>possible adverse effects discussed</p>
</li>
</ul>
</li>
<li>
<p>baseline CK if;</p>
<ul>
<li>
<p>personal / fhx of statin intolerance</p>
</li>
<li>
<p>personal / fhx of muscle disease</p>
</li>
<li>
<p>concurrent medicines that may increase risk of myalgia</p>
</li>
<li>
<p>risk factors for statin associated muscle damage</p>
</li>
</ul>
</li>
</ul>
<h5 id="management-of-statin-myalgia">management of statin myalgia</h5>
<ul>
<li>
<p>commonly reported</p>
<ul>
<li>avoid unnecessary discontinuation of treatment</li>
</ul>
</li>
<li>
<p>differential</p>
<ul>
<li>
<p>myalgia associated with phsyical activity likely to be self-limiting</p>
</li>
<li>
<p>acute onset with URTI = viral infectin</p>
</li>
<li>
<p>swelling/warmth = localised inflammation/infection</p>
</li>
<li>
<p>with poor sleep wuality + stress: Fibromyalgia</p>
</li>
<li>
<p>with mornign stiffness</p>
<ul>
<li>PMR</li>
</ul>
</li>
<li>
<p>slow onset</p>
<ul>
<li>
<p>hypothyroidism</p>
</li>
<li>
<p>hypercalcaemia</p>
</li>
<li>
<p>severe vit D deficiency</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>request CK/Cr</p>
<ul>
<li>CK doens’t prove statin induced myalgisa</li>
</ul>
</li>
<li>
<p>symptom based approach</p>
<ul>
<li>
<p>muscle pain but no increase CK</p>
<ul>
<li>
<p>reduce statin/discontinuation</p>
</li>
<li>
<p>don’t monitor CK</p>
</li>
</ul>
</li>
<li>
<p>with CK 3-10x noral</p>
<ul>
<li>
<p>reduce/discontinue</p>
</li>
<li>
<p>symptoms and CK regularly monitored if treatment continued</p>
<ul>
<li>weekly</li>
</ul>
</li>
</ul>
</li>
<li>
<p>CK >10x ULN</p>
<ul>
<li>discontinued immediately</li>
</ul>
</li>
</ul>
</li>
<li>
<p>rechallenge at original/lower dose</p>
<ul>
<li>
<p>sensitivity/specificity of w/d and retrial unkown</p>
</li>
<li>
<p>STOMP trial = 4.6% experienced myalgia during controlled withdrawal and rechallenge</p>
</li>
</ul>
</li>
<li>
<p>if causal relationship found</p>
<ul>
<li>
<p>discuss benefit/risks</p>
</li>
<li>
<p>trial of pravastatin</p>
</li>
</ul>
</li>
<li>
<p>most ldl-c lowering benefit of statin occurs at lower doses</p>
</li>
<li>
<p>consider alternate day</p>
</li>
<li>
<p>may benefit from non-statin lipid-lowering medicines</p>
<ul>
<li>
<p>gembibrozil</p>
</li>
<li>
<p>nicotinic acid</p>
</li>
</ul>
</li>
</ul>
<h4 id="interacting-medication-and-max-simvastatin-dose">Interacting medication and max. simvastatin dose</h4>
<ul>
<li>
<p>potent CYP3a4 inhibitors</p>
<ul>
<li>
<p>macrolide abx erythyromycin/clarithromycin</p>
</li>
<li>
<p>azole</p>
</li>
<li>
<p>protease inhibitor</p>
</li>
<li>
<p><strong>contraindicated</strong></p>
<ul>
<li>
<p>use alternative / stop simvastatin</p>
</li>
<li>
<p>use with caution and monitor closely atorvasstatin</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>moderate</p>
<ul>
<li>
<p>Amiodarone</p>
</li>
<li>
<p>verapamil</p>
</li>
<li>
<p>diltiazem</p>
</li>
<li>
<p>amlodipine</p>
</li>
<li>
<p>nicotinic acid (>1g/day)</p>
</li>
<li>
<p><strong>don’t exceed 20mg simvastatin</strong></p>
</li>
<li>
<p>use with caution</p>
</li>
</ul>
</li>
<li>
<p>minor</p>
<ul>
<li>
<p>azithromycin</p>
</li>
<li>
<p>roxithromycin</p>
<ul>
<li>
<p>case reports</p>
</li>
<li>
<p>use with caution simvastatin</p>
</li>
<li>
<p>ok with atorvastatin</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>INDUCERS</p>
<ul>
<li>
<p>carbamazepine</p>
</li>
<li>
<p>phenytoin</p>
</li>
<li>
<p>rifampicin</p>
</li>
<li>
<p>st. john’s wort</p>
</li>
<li>
<p>probable reduction in plasma concentration of statin</p>
<ul>
<li>monitor closley</li>
</ul>
</li>
</ul>
</li>
<li>
<p>consider a simvastatin dose reduction (<strong>max = 10mg</strong>) with: </p>
<ul>
<li>
<p>fibrates,</p>
</li>
<li>
<p>systemic fusidic acid, </p>
</li>
<li>
<p>colchicine, </p>
</li>
<li>
<p>renal impairment</p>
</li>
</ul>
</li>
</ul>
<h4 id="statin-safety-monitoring">Statin safety monitoring</h4>
<ul>
<li>
<p>generally safe</p>
</li>
<li>
<p>Monitoring LFT not necesasry --> risk of liver toxicity negligible</p>
</li>
<li>
<p>Monitoring CK not required in those asymptomatic</p>
</li>
<li>
<p>CK for unexplained muscle pain, tenderness or weakness</p>
<ul>
<li>
<p>Risk of myopathy usually dose related; increased in</p>
<ul>
<li>
<p>elderly; </p>
</li>
<li>
<p>combination treatments</p>
</li>
<li>
<p>pre-existing muscle, liver or kidney</p>
</li>
<li>
<p>high dose</p>
</li>
<li>
<p>intercurrent illness</p>
</li>
<li>
<p>frailty</p>
</li>
</ul>
</li>
<li>
<p>For muscle pain without CK rise: dose reduciton/discontinuation may be required</p>
</li>
</ul>
</li>
<li>
<p>CK rise 3-10x normal with symptoms: dose reduction/discontinuation with regular weekly monitoring of symptoms and CK is appropriate</p>
</li>
<li>
<p>CK risk >10x normal with symptoms; discontinue immediately</p>
</li>
</ul>
<p>= no longer necessary to monitor Liver unless speicic risk factors or signs of liver dyfunction/misle prolnes</p>
<ul>
<li>
<p>used with caution ALT 3x noraml</p>
</li>
<li>
<p>discontinued  CK10x > ULN</p>
</li>
</ul>
<h3 id="nicotinic-acid">Nicotinic acid</h3>
<ul>
<li>
<p>adjunct to statin or used alone</p>
</li>
<li>
<p>CI - bleeding</p>
</li>
<li>
<p>initially 100mg tds - increase to 1g tds</p>
</li>
</ul>
<h3 id="ezetimibe">Ezetimibe</h3>
<ul>
<li>
<p>adjunct to dietary and statin</p>
</li>
<li>
<p>10mg od</p>
</li>
</ul>
<h3 id="fibrates">Fibrates</h3>
<ul>
<li>
<p>decrease serum TAGs</p>
</li>
<li>
<p>variable effects on LDL</p>
</li>
<li>
<p>first line on ly in those whose serum TAG concentration > 10 or in those who cannot tolerate a statin</p>
</li>
<li>
<p>bezafibrate</p>
<ul>
<li>
<p>200mg tds normal release</p>
</li>
<li>
<p>500mg od modified release</p>
</li>
<li>
<p>400mg daily if eGFR 40-60</p>
</li>
<li>
<p>200mg q1-2d if eGFR 15-40</p>
</li>
<li>
<p>avoid if \&lt; eGFR \&lt;15</p>
</li>
<li>
<p>avoid with statin - increase myalgia</p>
</li>
</ul>
</li>
<li>
<p>gemfibrozil</p>
<ul>
<li>600mg bd</li>
</ul>
</li>
</ul>
      </div>
    </div>

  </div>
    

    <div class="footer">
        <p>Website powered by <a href="http://urubu.jandecaluwe.com">Urubu</a></p>
    </div>


</div> 


    <!-- jQuery (necessary for Bootstrap's JavaScript plugins) -->
    <script src="https://code.jquery.com/jquery.js"></script>
    <!-- Include all compiled plugins (below), or include individual files as needed -->
    <script src="//netdna.bootstrapcdn.com/bootstrap/3.2.0/js/bootstrap.min.js"></script>

  </body>
</html>
